Next Generation Sequencing (NGS) Market Size, Share & Global Report Analysis By Type (Whole Exome Sequencing, RNA Sequencing, CHIP Sequencing, De Novo Sequencing and Whole Genome Sequencing), By Product (Platforms, Services, Bioinformatics and Services) Application (Reproductive Health, Personalized Medicine, Agriculture and Animal Research), Industry Forecast, 2016–2026 - By Innovation Market Research

 Pulichser: 99strategy

November 2021

 Pages: 100

 IMR 1766

The global next-generation sequencing (NGS) market is anticipated to rise to a significant valuation by the end of 2022. Next-generation sequencing (NGS) is a DNA sequencing technology, which has revolutionized genomic research. It has emerged as an everyday research tool for researchers to study biological systems rapidly yet precisely. In research laboratories and academic institutes, the technology is increasingly superseding conventional methods such as Sanger sequencing. The market is expected to gain remarkable traction over the forecast period (2016 to 2026) with increasing applications of NGS.

Launch of efficient and rapid NSG-based in vitro (IVD) diagnostic products is likely to augment the market. For instance, in November 2017, Illumina, Inc. announced the launch of its NextSeq™ 550Dx instrument, a CE-IVD marked and FDA-regulated NGS system. The instrument includes a research mode and a diagnostic mode, which renders it possible to develop an array of IVD assays and perform clinical research on a single platform. It also provides a fully integrated, and mounted analysis software with modular software architecture to facilitate current as well as future assays.

Development of novel products and services by key players and their approval by regulatory bodies such as CE and FDA can provide an up thrust to the market. To put this in perspective, in the same month, FDA approved IMPACT, the tumor-profiling test by Memorial Sloan Kettering (MSK) Cancer Center. It is an IVD test that uses next-generation sequencing to rapidly identify the presence of 468 unique genetic mutations. The approval of this test will reduce burden on test providers. IMPACT The test works by comparing patient’s “normal” sample of tissues or cells to tumor tissues to detect genetic mutations, which might help in deciding treatment options.

Growing utilization of advanced platforms for the development of personalized/customized medicines is estimated to stoke growth of the next generation sequencing (NSG) market. According to a report available on Radiant Insights, Inc.; increasing implementation of pre-sequencing protocols can further stimulate the growth of the market. Rising uptake of the NGS technology by drug developers and scientists as a tool to gain insights into the genetic organization of various organisms can propel the market.

North America is expected to be a key revenue contributor throughout the forecast period (2016–2026), due to the presence of an advanced HCIT infrastructure. Some of the key players in the market are CapitalBio Corporation, Thermo Fisher Scientific, Berry Genomics Co. Ltd., Roche, and Qiagen.

Innovation Market Research. offers a plethora of tailor-made and syndicated reports for various domains, including healthcare, chemicals, medical devices, energy, materials, and technology. Each report is collated using data from both primary and secondary types of research.

Please fill in the form below to Request for Customized Report
Your personal details are safe and secured with us. Privacy Policy

To request sample copy of this report, please complete the form below verified and secure

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report. This also includes a 30 minute free analyst discussion post report purchase.

Your personal details are safe and secured with us. Privacy Policy

    What Information does this report contain?

Purchase Options

Offers & Discounts

  • Chapter purchase
  • Historical market data
  • Country level data breakdown
  • Free customization*
  • Discounts for first time
  • Special pricing for
              non-business entities


  • We offer 20% free customization on every purchase.

Get in touch!

  +91 810 895 3541